Wide Ranks

HUMA

Humacyte, Inc.

4.40

Top Statistics
Market Cap 566 M Forward PE -5.10 Revenue Growth 0.00 %
Current Ratio 1.10 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -5.23 Enterprise / Revenue Price To Sales Trailing12 Months
Profitability
Profit Margins 0.00 % Operating Margins
Balance Sheet
Total Cash 20 M Total Cash Per Share 0.1630 Total Debt 17 M
Total Debt To Equity Current Ratio 1.10 Book Value Per Share -0.5320
All Measures
Short Ratio 541.00 % Message Board Id finmb_107706507 Shares Short Prior Month 16 M
City Durham Uuid bb940349-63c0-3d15-9ca4-a6ea35181ed8 Previous Close 4.43
First Trade Date Epoch Utc 1 B Book Value -0.5320 Beta 1.47
Total Debt 17 M Volume 2 M Fifty Two Week Low 2.45
Total Cash Per Share 0.1630 Shares Short Previous Month Date 1 B Target Median Price 12.00
Max Age 86400 Recommendation Mean 1.43 Sand P52 Week Change 0.3133
Target Mean Price 13.00 Net Income To Common -152867008 Short Percent Of Float 0.1917
Implied Shares Outstanding 128 M Trailing Peg Ratio None Last Fiscal Year End 1 B
Average Daily Volume10 Day 3 M Average Volume10days 3 M Total Cash 20 M
Next Fiscal Year End 1 B Held Percent Insiders 0.2687 Trailing PE 0.0000
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 4.43
Target Low Price 6.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 5.26
Open 4.45 Free Cashflow -58331500 State NC
Dividend Yield 0.00 % Return On Assets -0.5323 Time Zone Short Name EST
Trailing Eps -1.34 Day Low 4.39 Address1 2525 East North Carolina Highway 54
Shares Outstanding 128 M Price Hint 4 Target High Price 25.00
Website https://www.humacyte.com 52 Week Change 0.6604 Average Volume 3 M
Forward Eps -0.8600 Recommendation Key strong_buy Compensation As Of Epoch Date 1 B
Quick Ratio 98.20 % Is_sp_500 False Regular Market Day High 4.74
Profit Margins 0.00 % Fifty Two Week High 9.97 Day High 4.74
Shares Short 19 M Regular Market Open 4.45 Industry Key biotechnology
Earnings Growth 0.00 % Revenue Growth 0.00 % Shares Percent Shares Out 0.1488
Operating Cashflow -90599000 Currency USD Time Zone Full Name America/New_York
Market Cap 566 M Is_nasdaq_100 False Zip 27713
Quote Type EQUITY Industry Biotechnology Long Name Humacyte, Inc.
Regular Market Day Low 4.39 Held Percent Institutions 0.3001 Current Price 4.40
Enterprise To Ebitda -5.23 Financial Currency USD Current Ratio 1.10
Industry Disp Biotechnology Number Of Analyst Opinions 7 Country United States
Float Shares 91 M Two Hundred Day Average 5.42 Enterprise Value 550 M
Forward PE -5.10 Regular Market Volume 2 M Ebitda -105277000
Exchange NMS
Go to Yahoo Finance Go to Seeking Alpha 
Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas.

The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.

It is developing a portfolio of HAVs, which would target the vascular repair, reconstruction, and replacement market, including vascular trauma; arteriovenous access for hemodialysis; peripheral arterial disease; pediatric heart surgery; and coronary artery bypass grafting, as well as for the delivery of cellular therapy, including pancreatic islet cell transplantation to treat Type 1 diabetes.

The company was founded in 2004 and is headquartered in Durham, North Carolina.